Mycoplasma and viral infections often radically change host cell metabolism in vitro (2, 4, 5) . Because of the seriousness of the resultant diseases, more progress has been made in the study of viruses than mycoplasmas. Mycoplasmas are the smallest of procaryotic organisms. Mycoplasmas or their products have been shown not only to inhibit the stimulation of lymphocytes by allogeneic cells or mitogens but also to serve as mitogens for T and B lymphocytes (4) .
Historically, Copperman and Morton first described (in 1966) the inhibition of mitosis in lymphocyte cultures by Mycoplasma hominis (5) . In 1968, Barile and Levinthal reported that the inhibitory effect of M. hominis on phytohemagglutinin-mediated lymphocyte stimulation was due to depletion of arginine from the growth medium (2) . In 1963, Schimke and Barile had shown that arginine is a major energy source for nonfermentative mycoplasma species which convert prodigious amounts of arginine to citrulline and ornithine via the arginine dihydrolase pathway (12) . For almost 3 decades since then, it has been believed that the mycoplasma suppressive effect is mainly due to the depletion of arginine from the nutritional source for cells.
Recently, we identified a lymphocyte blastogenesis inhibitory factor (LBIF) in the culture supernatant of human histiocytic lymphoma U937 (16, 17) . The factor was purified by fast protein liquid chromatography (FPLC). LBIF is a single polypeptide chain, as estimated from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). LBIF shows a pl of approximately 4.5 upon chromatofocusing. Partial amino acid sequencing analysis shows that LBIF is a novel immunoregulatory factor. The cell growth inhibitory activity of LBIF was characterized by the growth of lectin-stimulated T lymphocytes (17) as well as various tumor cell lines (15) . In this study, we demonstrate that LBIF originates from a mycoplasma, M. arginini, and bears the arginine deiminase activity.
MATERIALS AND METHODS
Cell lines. Human histiocytic lymphoma U937 was obtained from H. Fujiwara, Habikino Hospital, Osaka, Japan, and coded as U937-F or from the American Type Culture Collection, Rockville, Md., and coded as U937-ATCC. A * Corresponding author.
human melanoma cell line, A375, was provided by Hayashibara Biochemical Laboratories, Inc., Okayama, Japan. U937-F is a producer of LBIF and has been shown to be infected with a mycoplasma, M. arginini, which was determined by metabolism inhibition tests (10), as described below.
Purification of LBIF. LBIF was purified from crude supernatant of a human histiocytic lymphoma cell line, U937-F, as described previously (16, 17) . Briefly, cells were cultured at 1 x 106 cells per ml in serum-free RPMI 1640 medium. The serum-free supernatant was concentrated by an ultrafiltration membrane module, AIL-1010 (Asahi Chemical Industry Co. Ltd., Tokyo, Japan). The crude concentration was fractionated on a DEAE-5PW TSK gel (21.5 mm by 15 cm) (Tosoh, Tokyo, Japan) equilibrated with 20 mM Tris hydrochloride (pH 7.7). The separation was done by a linear gradient from 0 to 0.5 M NaCl. LBIF activity was tested as described below. The active fractions were subsequently fractionated on a Mono P chromatofocusing column (HR 5/20; Pharmacia, Inc.). A fraction of LBIF was further resolved on a hydroxyapatite column (21 by 100 mm; TAPS-052110; Tonen, Tokyo, Japan). The purity of the LBIF preparation was assessed by SDS-PAGE and reversed-phase high-performance liquid chromatography of an RP-304 column (Bio-Rad Laboratories, Inc.), as described previously. The homogeneity of LBIF used in this study is indicated by the results shown in Fig. 2 . One unit of LBIF was defined as the amount of LBIF sample required to induce a halfmaximum response in the LBIF assay, as previously described. Approximately 10 ng of LBIF sample corresponds to 1 U. LBIF assay. The LBIF assay was originally performed by using interleukin-1 (IL-1)-stimulated murine thymocytes as described previously (16, 17) . Our experience showed that a human melanoma cell line A375 could be used as an indicator cell line in this LBIF bioassay. The sensitivity to detect LBIF is the same as that of the original LBIF assay. Furthermore, the LBIF assay using A375 cells is simple and much easier to handle than the original assay. In this study, the LBIF assay was done by using A375 cells, as described previously (14) . Briefly, A375 cells were cultured at born hamster less than 24 h old which had been pretreated with anti-hamster thymocyte serum, as described previously (7, 18) . After 3 weeks, U937 cells were recovered from animals, separated from dead cells by Ficoll-Hypaque separation solution, and cultured in vitro for 2 weeks. The U937 cells were determined to be mycoplasma-free by the mycoplasma detection protocols described above. The isozyme patterns (glucose-6-phosphate dehydrogenase, lactate dehydrogenase, and purine nucleotide phosphorylase) were also determined by using the Authenti Kit (Corning Glass Works, Corning, N.Y.) in order to confirm that the recovered cell line was U937.
Preparation of anti-LBIF antiserum. BALB/c mice were purchased from the Shizuoka Laboratory Animal Center (Hamamatsu, Japan). Mice were immunized intraperitoneally (i.p.) with 0.2 ml of Freund incomplete adjuvant containing 20 ,g of purified LBIF and 100 ,g of muramyldipeptide every 3 weeks. After four or five immunizations, polyclonal anti-LBIF serum was obtained.
Assay for enzymatic activity. L-Arginine (GIBCO) (1 mM)
was incubated with various concentrations of LBIF in 5 mM phosphate buffer, pH 6.5, at 37°C for 1 h (9). After heating the samples for 5 min, the reaction mixture was subsequently analyzed by the concentration of citrulline and ornithine by an amino acid analyzer (Hitachi-835; Hitachi, Japan) according to standard procedure. (Fig. 1) . The SDS-PAGE pattern of LBIF (U937 cell culture derived) employed throughout this study is seen in Fig. 2 . It should be noted that LBIF abruptly inhibited the growth of A375 cells at a very narrow concentration range (approximately 1.5 to 2.5 U/ml) (Fig. 1) (15, 15a, 17) .
LBIF produced by mycoplasma-infected cells. Although the molecular characterization of LBIF has been carried out, we have not extensively examined possible origins of the LBIF producers such as the U937 cells or infectious organisms (mycoplasmas or viruses). The U937-F cells employed in this study were previously reported to be mycoplasma-free, as judged by the absence of [3H]thymidine incorporation in the culture supernatant and negative staining with ethidium bromide-acridine orange (6) . However, we reexamined in this study the U937-F cell by using two highly sensitive mycoplasma detection procedures which have been recently developed. The results were that U937-F was clearly mycoplasma positive. Therefore, in order to determine which organism produces LBIF, we first attempted to clear mycoplasmas from U937-F cells and examine the LBIF production of mycoplasma-free U937-F cells. The clearance of mycoplasmas was done according to the in vivo passage procedure described previously (7) . Cells (1 x 106/ml) were cultured for 2 days. TIien, LBIF and mycoplasma were (11) . c Cells were prepared by the in vivo passage method with hamsters, as described previously (7).
d Mycoplasma-cleared cells were cultured in medium containing 30% culture supernatant of mycoplasma-infected U937-F cells for 7 days. examined in the supernatant and U937 cells, respectively. LBIF production was not detected in mycoplasma-cleared or mycoplasma-free U937 cells (Table 1) . However, when mycoplasma-free U937 cells were infected with mycoplasma contained in the supernatant of U937 cells, these cells again produced LBIF in the culture supernatant. The time course of LBIF production and mycoplasma growth were also examined in the culture of U937-F cells, showing that LBIF production paralleled mycoplasma growth (data not shown). We also investigated the possibility that reinfected U937 cells might produce a suppressor factor distinct from LBIF produced by U937-F cells. To do this, the culture supernatant of reinfected U937 cells was collected and fractionated by sequential FPLC by using DEAE-5PW, Mono P, and hydroxyapatite columns. The yield and effluent pattern of the suppressor factor at each step of the chromatography and the pl value and molecular weight estimated by SDS-PAGE were the same as those of LBIF. Furthermore, peptide mapping analysis and partial amino acid sequencing analysis confirmed that reinfected cells produced LBIF (unpublished data).
These results suggested two possibilities, one being that mycoplasma infection stimulated U937 cells to produce LBIF and the other being that mycoplasma produced LBIF.
M. arginini produces LBIF. To examine these possibilities, isolation and serological identification of mycoplasma were carried out. As a result, arginine-catabolizing mycoplasmas were isolated in high titers (107 CFU/ml of cell culture fluid). DEAE-5PW TSK gel (7.5 mm by 7.5 cm; Tosoh) under a linear gradient from 0 to 0.5 M NaCl and subsequently on a G3000 SWXL TSK gel (7.8 by 300 mm; Tosoh). LBIF activity was assayed on each fraction. A single peak of fractions with LBIF activity was detected in materials derived from mycoplasma culture. This elution pattern was identical to those of authentic LBIF on DEAE-5PW and TSK G3000 SWXL gels (Fig. 3) . These results suggested that M. arginini might produce LBIF.
Neutralization of mycoplasma-derived inhibitory factor with anti-LBIF antiserum. By using partially purified materials (Fig. 3) derived from mycoplasma culture, we determined whether mycoplasma inhibitory activity could be neutralized by anti-LBIF antiserum prepared by hyperimmunization with the purified LBIF. Anti-LBIF antiserum was added at various concentrations of LBIF in the LBIF assay system. Anti-LBIF antiserum almost completely neutralized the inhibitory activity of mycoplasma materials, whereas control serum did not (Fig. 4A) . The same results were obtained in the case of authentic LBIF (Fig. 4B) . Thus, considering these results collectively, it was concluded that LBIF was of M. arginini origin.
LBIF has arginine deiminase activity. It is believed that the mycoplasma suppressive effect is mainly due to the depletion of arginine from the nutritional source for cells, and arginine deiminase may be a candidate for a mycoplasmal inhibitory factor. Therefore, we first determined whether the addition of excess amounts of L-arginine could reverse the inhibiting activity of LBIF. Figure 5 clearly shows that LBIF activity was effectively blocked by the addition of L-arginine in dose-response fashion while not being affected by the addition of L-lysine, indicating that LBIF might be arginine deiminase or arginase. To answer this question, the product resulting from the incubation of the mixture of LBIF and L-arginine in vitro was determined (9) . In the case of arginine deiminase, the end products are citrulline and NH3, whereas arginase produces ornithine and urea. example of how mammalian cells can be used as the best carrier of a nutritional matrix for the growth of mycoplasmas. Mycoplasma-infected cells can often be cultured in a serum-free medium. Accordingly, we were easily able to purify the factor, LBIF, to homogeneity by FPLC from the serum-free supernatant of mammalian cells. This allowed us to analyze the amino acid sequence of LBIF and to prepare the antiserum specific to LBIF. It has been believed that an immunosuppressive substance derived from mycoplasmas may be the arginine deiminase which was suggested by a few classical studies published about 3 decades ago (2, 4, 5) . It was clearly demonstrated (Fig. 4 and Table 2 ) that LBIF bore the arginine deiminase activity.
In previous studies, we observed that LBIF is biologically very specific and its effects are exerted in a selective manner in vitro. LBIF does not inhibit IL-2 production or p55 IL-2 receptor expression (17) . Moreover, although LBIF drastically inhibits the constitutive growth of various tumor cell lines in vitro, there are several cell lines whose cell growth is not influenced by LBIF (15) . If these results are attributed to the simple nutritional depletion of L-arginine by arginine deiminase, L-arginine must play an important role in regulating cell growth and differentiation. In this regard, it has been reported that arginine deprivation inhibits the replication of tumor cells, parasites, and viruses and suppresses cellular immune functions in vitro (13) .
Hibbs et al. (8) showed that the activated macrophage cytotoxic effector system is associated with L-arginine deiminase activity and that the imino nitrogen removed from the guanido group of L-arginine by the deiminase reaction subsequently undergoes oxidation to nitrite. Thus, it has been suggested that arginine deiminase might induce multiple metabolic changes in mammalian cells. Furthermore, Albina et al. (1) recently demonstrated that the culturing of resident macrophages in L-arginine-free medium results in a generalized increase in activation-associated functions, not only morphologically pronounced spreading and elongation but also augumented tumoricidal activity, superoxide production, phagocytosis, and protein synthesis.
A number of studies have suggested that arginine-utilizing mycoplasma species can exert an immunosuppressive effect in vivo (4) . However, it is difficult to envisage how organisms could deplete a host of arginine. Thus 
